ArticleFrontiers in cellular and infection microbiology2026
Exploring the partial immunological mechanisms of hepatitis B virus reactivation in patients with hepatitis B and tuberculosis.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the immune changes caused by anti-tuberculosis treatment, especially the fluctuations of IFN-γ, and their role in HBV reactivation and related liver injury. Method: This was a retrospective study. Firstly, 162 patients with hepatitis B and tuberculosis co-infection (initial HBV-TB group) and 162 patients with simple hepatitis B infection (initial HBV group) who were hospitalized at the Third People's Hospital of Huizhou from June 2016 to September 2025 were consecutively included for preliminary comparison. Secondly, from the initial cohort, a baseline comparable subgroup was selected based on age, gender, and baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for immunological analysis (a total of 14 patients in the TB-HBV group and 11 patients in the HBV group).Additionally, within the HBV-TB group, according to whether they received preventive antiviral treatment, they were divided into an untreated subgroup (n=16) and a treated subgroup (n=20) to analyze the impact of treatment on prognosis. Result: The comparison of baseline data between the HBV-TB group and the HBV group showed that the proportion of males was higher in the HBV-TB group, and the levels of WBC, NEU, Mon and PLT were higher than those in the HBV group. However, the levels of HBsAg, HBVDNA, ALT, AST, Lym and RBC were lower than those in the HBV group (all P<0.05). Among HBV-TB patients who did not receive anti-HBV treatment, 81.25% of the patients(13 case)had HBV reactivation, and 43.75% of them (7case)had severe liver injury. The incidence of Drug-induced liver injury(DILI) and the rate of HBV reactivation in this group were both higher than those in the anti-HBV treatment group (all P<0.05). In terms of immune indicators, the counts of lymphocytes, total T cells and CD4+ T cells in the HBV-TB group were all lower than those in the HBV group, while the levels of IFN-γ and IL-6 were higher(all P<0.05). Conclusion: It is recommended that HBsAg screening be conducted for all tuberculosis patients before anti-tuberculosis treatment, and preventive antiviral treatment be given to individuals with positive HBsAg to reduce the risk of HBV reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.